Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Treace Medical Concepts › 14K TMCI shares were withheld to cover taxes or exercise cost (CEO) Insider trades
Why it stands out Routine share withholding; mechanical by default.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Jan 22, 2026
Reporting period Not applicable
Filed with the SEC Jan 24, 2026 CEO Tax withholding
Context Classification tax withholding
Code F — shares delivered to pay exercise price or tax liability
Planned / mechanical clue Tax mechanics (code F)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001193125-26-021449
Filed / recorded
Jan 24, 2026, 2:30 AM UTC
Added to OQRO Oct 7, 2026, 11:38 PM UTC
Data quality Verified: identifiers matched exactly
Issuer TREACE MEDICAL CONCEPTS, INC.
Reporting person John T. Treace
Relationship Director, Officer, 10% owner
Officer title Chief Executive Officer
Table Non-derivative (Table I)
Transaction date Jan 22, 2026
Acquired / disposed Disposed (D)
Shares owned after 6,761,633
Footnotes from the filing Includes 321,871 restricted stock units.
Around the same time Insider filing
Traded Feb 10 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Feb 10 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Jan 22 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Dec 16, 2025 Company filing · Form 8-K · Material agreement, Agreement ended Signed an important agreement, and ended an important agreement (and 4 more items) Jan 13, 2026 Company filing · Form 8-K · Results, Reg FD Reported its results, and shared information with investors What came next Feb 27, 2026 Company filing · Form 8-K · Results Reported its results Apr 8, 2026 Company filing · Form 8-K · Results, Executive change Changed a top executive or board member, and reported its results (and 1 more item) “Effective as of the close of business on April 8, 2026, Gaetano M. Guglielmino, Chief Commercial Officer of Treace Medical Concepts, Inc. (the “Company”), will depart from the Company.” May 8, 2026 Company filing · Form 8-K · Results Reported its results May 12, 2026 Insider · First insider buy since Mar 2025 CEO purchased ~$93K of TMCI shares in the open market May 13, 2026 Insider CEO purchased ~$121K of TMCI shares in the open market May 14, 2026 Insider CEO purchased ~$161K of TMCI shares in the open market